Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old
- You have been diagnosed with depression (based on DSM-5 guidelines) and have recently started taking Vortioxetine (for no more than one week)
- You have depression and may also have symptoms of anxiety
- Your depression is rated as moderate to severe based on a standard scoring scale (HAM-D score above 18)
- You have been diagnosed with episodic migraine (with or without aura) for at least one year before the study screening visit, and your migraines started before you were 50 years old
- You are not currently taking any other treatments for depression alongside Vortioxetine
- You are not currently on certain migraine prevention medications, such as older antidepressants (TCAs), other antidepressants, anti-CGRP injections, or gepants, and you are not considered a suitable candidate for anti-CGRP injections
- Your current migraine treatment has been stable for at least two months and is not expected to change in the next 12 weeks
- You are willing and able to provide written consent to participate
Who may not be able to join:
- You have another significant pain condition, such as chronic back pain or fibromyalgia, that could affect the results
- You have been diagnosed with certain other types of headache disorders, such as chronic tension-type headache, cluster headache, hypnic headache, hemicrania continua, new daily persistent headache, hemiplegic migraine, or migraine with brainstem aura
- You have a personal history of psychosis or bipolar disorder (manic episodes)
- You have signs of cognitive (memory or thinking) difficulties, based on a standard screening test (confirm with trial site)
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Catello Vollono, MD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +390630154279
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Response to Vortioxetine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.